An antibody treatment developed by AstraZeneca has revealed the ability to both treat and prevent Covid-19.
A request was submitted to the US Food and Drug Administration (FDA) last week for emergency use authorisation for AZD7442, which consists of two antibodies.
When compared to a placebo, AZD7442 was more effective in preventing severe disease in non-hospitalised patients who presented mild to moderate Covid-19 symptoms.
During its Tackle trial, which consisted of 903 people who were at high risk of progression to severe Covid-19, it was found that a single dose of 600mg of AZD7442 injected into the muscle managed to reduce the risk of developing severe Covid-19 or death by 50%, when compared to the placebo.
Professor of intensive care medicine at University College London Hugh Montgomery stated, “With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations from getting Covid-19 and can also help prevent progression to severe disease.”
The treatment has been billed as suitable for those who cannot have a regular vaccination, who respond negatively to Covid-19 vaccines or whose health conditions put them at risk of serious illness.
IMAGE – “201214-D-BN624-0811” (CC BY 2.0) by U.S. Secretary of Defense